Investment
Features
FeesSafety
Academy
More
Pluang+

Revival Gold sells 51% stake in Diamond Mountain phosphate project to Canadian Phosphate for cash and shares.

Company Fundamentals
29 Jul 2026
Newsfile Corp
View Source
Neutral
pluang ai news

Revival Gold has completed the sale of its 51% interest in the Diamond Mountain phosphate project to Canadian Phosphate, receiving US$127,500 in cash and shares valued at about US$270,000. The deal also includes future cash payments totaling US$1,020,000, with options to receive payments in shares. This sale allows Revival Gold to focus on its core gold projects in the US while benefiting from potential future production at Diamond Mountain.

More News

Halper Sadeh LLC investigates if UTZ, BLFS, NRIM shareholders get fair deals in recent sales and mergers

Halper Sadeh LLC investigates if UTZ, BLFS, NRIM shareholders get fair deals in recent sales and mergers

Halper Sadeh LLC is investigating whether the sales and mergers involving Utz Brands, BioLife Solutions, and Northrim BanCorp provide fair financial terms to their shareholders. The firm suspects insiders might gain benefits not available to ordinary...

Market News
Bearish
2 hours ago
Mesoblast reports $115M Ryoncil revenue in first year post-FDA approval, expands trials for serious inflammatory diseases.

Mesoblast reports $115M Ryoncil revenue in first year post-FDA approval, expands trials for serious inflammatory diseases.

Mesoblast announced $36 million in net revenue for Q4 and $115 million for the first full year following FDA approval of its Ryoncil therapy, used to treat steroid-refractory acute graft versus host disease (SR-aGvHD) in children. The company is expa...

Company Fundamentals
Bullish
3 hours ago
Fortuna approves 30% expansion of Séguéla Gold Mine to boost production and recoveries.

Fortuna approves 30% expansion of Séguéla Gold Mine to boost production and recoveries.

Fortuna Mining Corp. has approved a $109 million expansion of its Séguéla Gold Mine in Côte d’Ivoire, increasing processing capacity by 30% from 1.75 to 2.3 million tonnes per annum and improving gold recovery to 94.5%. This expansion includes upgrad...

Company Fundamentals
Bullish
3 hours ago
BeOne Medicines shifts to a multi-asset cancer platform with 35.5% revenue growth in Q1 2026

BeOne Medicines shifts to a multi-asset cancer platform with 35.5% revenue growth in Q1 2026

BeOne Medicines is evolving from relying on its BRUKINSA drug to becoming an integrated hematology and oncology company with multiple growth drivers. In Q1 2026, the company reported a 35.5% increase in revenue, expanding profit margins, and rising p...

Company Fundamentals
Bullish
4 hours ago
Quantum BioPharma settles CAD$123K debt by issuing shares to creditors

Quantum BioPharma settles CAD$123K debt by issuing shares to creditors

Quantum BioPharma has closed a debt settlement by issuing 30,948 Class B subordinate voting shares worth CAD$123,487.43 to its creditors. The shares were priced at CAD$3.99 each, based on the previous trading day's closing price on the Canadian Secur...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App